FasL expression is critical in T-cell activation-induced apoptosis, which is involved in lupus pathogenesis. This study identified two SNPs in the FasL promoter regions from -1145 to -45 by genomic DNA sequencing. The -844C/T polymorphism was previously described by its location in and affect on the CCAAT/enhancer-binding protein b (C/EBPB b)-binding site and the other (-1094A/C, a novel polymorphism) was located at the NF-kB transcription-binding site. FasL gene promoter polymorphisms were genotyped in 260 systemic lupus erythematosus (SLE) patients and 280 healthy controls using MassArray matrix-assisted laser desorption ionization-time-of-flight (MALDI-TOF) mass spectrometry. The distribution of FasL promoter -844C/C genotype, predominant in Taiwanese, was skewed in Taiwanese SLE patients (odds ratio: 1.53; P-value ¼ 0.014). FasL promoter À844C/T polymorphism genotype distributions of Taiwanese, African Americans, and Caucasians differed. Moreover, no particular clinical association of À844C/T and À1094A/C polymorphisms with SLE was found in patients in Taiwan. This study confirmed that À844C/C genotype is associated with lupus susceptibility. The -1094A/C polymorphism is not significantly associated with lupus disease susceptibility, albeit the role of NF-kB pathway in FasL promoter activation remains unclear. Fas/FasL pathway may contribute to SLE polygenic disease entity.
Introduction
Systemic lupus erythematosus (SLE), a multifactorial and polygenic autoimmune disease, is characterized by the production of various autoantibodies against nucleoproteins and subsequent induction of organ damage. 1 Apoptosis, or programmed cell death, is a genetically controlled process of cell destruction that clears dead cells without the release of intracellular contents into the extracellular microenvironment. 2 SLE patients have displayed increased apoptosis of lymphocytes, particularly T cells, neutrophils, and monocytes. [3] [4] [5] [6] [7] [8] Defective apoptosis is thus a vital part of SLE pathogenesis. Furthermore, altered monocyte phenotypes and neutropenia lead to impaired recognition and clearance of apoptotic cells, and correlate with anti-dsDNA and disease activity. 6, [9] [10] [11] Fas ligand (FasL), a trimeric type II membrane protein, belongs to the TNF receptor family that induces apoptosis of cells bearing Fas receptor. 12 Observations in mouse models of SLE demonstrated that mice with Fas (MRL/lpr) or FasL (gld) mutations developed lymphadenopathy with accumulation of CD4ÀCD8À double negative lymphocytes. [13] [14] Similarly, autoimmune lymphoproliferative syndromes (ALPS, also called 'Canale-Smith syndrome') in humans with dominant Fas, FasL, or caspase 10 mutations are associated with loss of lymphocyte regulation leading to accumulations of double negative T cells and B cells. The clinical characteristics are lymphoadenopathy, splenomegaly, polygammaglobulinemia, and SLE-like systemic autoimmunity. [15] [16] [17] [18] Abnormal expression of FasL on lymphocytes and apoptosis triggering has been demonstrated in SLE patients. [19] [20] [21] [22] Anti-FasL antibody, which inhibits Fas/FasL-mediated apoptosis, can be detected in SLE patients. 23 The enhanced serum levels of soluble Fas demonstrated that the intriguing effect of the Fas/FasL pathway on cell death was related to disease activity. [24] [25] [26] These findings indicate that in SLE patients, the Fas/ FasL pathway plays an important role in immune homeostasis and maintenance of self-tolerance. However, gene mutation in the coding regions of FasL rarely occurs in human lupus patients. [27] [28] Thus, this study asks whether the genetic difference in the FasL promoter site influences FasL expression and SLE disease pathogenesis. This study investigated SNPs flanking the FasL promoter region in Taiwanese SLE patients. Two SNPs, À844C/T and À1094A/C, were located inside a motif of CAAT/enhancer-binding protein b and in the NF-kBbinding site, respectively. Subsequently, the association of À844C/T and À1094A/C with susceptibility to and clinical characteristics of SLE in Taiwanese patients was analyzed. 
Results

Clinical characteristic of SLE patients
FasL promoter polymorphism detection
No definite SNP located in the FasL coding region was revealed in previous studies. This study focuses on identifying promoter SNPs. Direct sequencing of PCR products from 20 Taiwanese patients was performed. We sequenced 1100 base pairs of the FasL promoter from À1145 to À45 to identify polymorphisms. Two SNPs at À844 and À1094 on the distal FasL promoter site were identified. The other previously reported SNPs were not detected in Taiwanese. The À844C/T site was recently mapped to the CCAAT/enhancer-binding protein b (C/EBPB b)-binding region and this protein showed an allele-specific difference in binding affinity. The À1094A/C site was mapped to an NF-kB-like-binding region using TESS (Transcription Elements Search Software, http://www.cbil.upenn.edu/tess/).
Associations of FasL promoter polymorphisms with SLE and clinical characteristics
This study applied high-throughput MassArray matrixassisted laser desorption ionization-time-of-flight (MALDI-TOF) mass spectrometry SNP genotyping to identify FasL polymorphisms in 260 SLE patients and 280 healthy controls. The -844C/T promoter polymorphism demonstrated a modest association (P-value ¼ 0.05) with susceptibility to SLE in Taiwanese patients. Meanwhile, the distribution of À844C/C genotype (P-value ¼ 0.014 in comparison to À844C/T þ À844T/T) and À844C allele (P-value ¼ 0.023) was skewed in Taiwanese SLE patients (Table 2 ). In contrast, no significant difference was found in the incidence and distribution of the À1094A/C polymorphism between the Taiwanese SLE and controls. No significant difference in the distribution of À844C/T and À1094A/C polymorphisms was found in Taiwanese SLE patients grouped according to age at onset. Additionally, no apparent difference in distribution of these two SNPs was found between those with positive vs negative clinical manifestations and between those with positive vs negative serologic findings. Similarly, in those homozygous for both À844/C/T with À1094A/C, no synergistic effect on SLE disease susceptibility or clinical characteristics was detected. Moreover, the distribution of the FasL À844C/T promoter polymorphism clearly differed between Caucasian, African American, and Taiwanese patients ( Table 3 ). The À844C/ C genotype was most frequent in Taiwanese individuals and the À844T/T genotype was most frequent in African Americans. Despite reverse distribution of the À844C/T genotypes, the À844C/C genotype was a risk factor for SLE in Taiwanese and African Americans individuals. 
Discussion
Apoptotic and necrotic cells have been shown to be the major sources of nuclear autoantigens of SLE pathogenesis. The autoantigens trigger autoantibody production and subsequently induce systemic autoimmunity, leading to formation of many apoptotic blebs. [32] [33] FasL is mainly expressed in activated T cells, NKT cells, and immune privilege sites. FasL-expressing activated T cells are the major cause of activationinduced apoptosis in T cells, antigen-presenting cells, and B cells. 13, 34 T cells in SLE patients express significantly higher amounts of FasL that interact with TCR and CD28 signaling pathways accounts for the accelerated apoptosis seen in lymphocytes from SLE patients. 20, 30 The excess of lymphocyte apoptosis and deficient phagocyte-mediated clearance of apoptotic cells could contribute to B-cell hyperactivity and subsequent autoantibodies overproduction. [9] [10] 12 Taken together, these findings suggest that molecular mechanisms regulating FasL gene expression are crucial to SLE autoimmunity.
The inducible regions of the human FasL promoter have been mapped by deletion and mutational analysis and include the basic regulatory region between À273 and the transcription start site, a region between À431 and À273 responsible for enhanced regulatory transcription, a negative regulatory region between À473 and À900, and another region from À900 to À1200 possibly responsible for enhanced regulatory transcription. Several transcription factors such as NF-AT, Egr, AP-1, and SP-1 have been demonstrated to be critical transcription factors participating in FasL gene expression. 30 Sequencing 1090 bps that contains the three regulatory regions of the FasL promoter found no polymorphic sites located within these transcription factor motifs. This finding indicates that several factors other than intrinsic FasL promoter differences in cis-regulatory response elements are potentially involved in FasL expressions related to activated T-cell-induced cell death.
Genetic association studies require adequate matching of cases and controls to avoid hidden population stratification and reproducible results. 35 This study displayed similar distribution of two FasL SNP genotype frequencies in each set of MALDI-TOF samples. This indicates the replicate results and homogenous population admixture. The À844C/T polymorphism, located at the binding motif of CAAT/enhancer-binding protein, displayed different distributions and susceptibility to SLE among three distinct ethnic groups. 31 This casecontrol study confirmed that individuals with À844C/C genotype (exhibiting higher basal FasL expression in transfected fibrocytes) are more susceptible to SLE in Taiwanese, although display reverse distributions of À844C/T polymorphism to African Americans. In contrast, À844C/C genotype did not increase disease susceptibility risk in Caucasians in previous studies of autoimmune-related diseases, including SLE, type I insulin-independent diabetes mellitus, and autoimmune thyroid diseases. 31, [36] [37] [38] Moreover, the frequency of -844C/T polymorphism was not significantly different in patients with positive vs negative clinical manifestations and autoantibodies. These findings indicate that lupus pathogenesis is complex and multiple genetic defects might be required for development of the full-blown disease. Another plausible explanation for the modest association of SLE with diverse ethnic distributions of À844C/T polymorphism is that there is a possible linkage disequilibrium effect and that the true susceptibility gene of SLE is located near the FasL gene. Off offspring of Hashimoto's thyroiditis.
Fas ligand promoter polymorphism of SLE in Taiwan J-Y Chen et al
Several previous studies have demonstrated that NFkB plays a crucial role in human FasL expression during T-cell receptor stimulation and stress-induced DNA damage. [39] [40] [41] [42] [43] [44] Li-Weber et al identified two NF-kB-binding sites localized at À537 to À521 and À57 to À47 of the human FasL promoter. Two base pairs substitutions mutational analysis of both sites resulted in reduced FasL promoter activity. The distal NF-kB-binding site revealed no influence of FasL promoter activity in response to T-cell activation. 43 Conversely, Kasibhatla et al [44] [45] identified another NF-kB-binding site located between À1.2 kb and À0.9 kb in the distal FasL promoter region by comparing activation of T cell with FasL reporter construct of different lengths (between the À1.2 and À0.9 kb). The À1.2 kb reporter construct enhanced FasL promoter activity and contributed to the FasL promoter activity of the distal promoter site region. Notably, the conflicting promoter activities induced by this human distal FasL promoter NF-kB binding site were considered due to a DNA sequence difference in the NF-kB cis-regulatory motif (AGA/CAAGTCCC), which is located at the site of the À1094A/C polymorphism detected in this study. 30 The present study revealed an insignificant association between À1094A/C polymorphism and SLE susceptibility in Taiwanese individuals, although the functional significance of NF-kB pathway on FasL gene expression requires further characterization.
In conclusion, this study identified two FasL promoter polymorphisms in Taiwanese individuals. Those with FasL À844C/C genotype, expressed higher FasL as demonstrated by Wu et al, 31 exhibited a modest association with SLE disease susceptibility in Taiwan. FasL À1094A/C polymorphism, located on the NF-kB transcription-binding site, demonstrated an insignificant skew distribution of SLE patients in Taiwan. FasL expression was found to be the complex result of transcriptional regulation and interaction involving other receptor pathways. FasL promoter gene variation is one of the extremely complex genetic factors contributing to SLE pathogenesis.
Patients and methods
Patients
A total of 260 patients with SLE and 280 healthy controls (blood donors (mean age 33.1710.7; range, 18-58 years old) selected on the basis of responses to a questionnaire survey to exclude autoimmune diseases) were enrolled. The SLE patients were judged by rheumatology specialists to meet the 1982 and 1997 American College of Rheumatology (ACR) criteria for SLE and were prospectively followed up in the rheumatology clinics of Chang Gung Memorial Hospital. Clinical manifestations of lupus and related serological findings were assessed on the basis of the ACR criteria. Patients were classified as positive or negative within the first year of lupus diagnosis. Associated infections during the disease course were recorded, and were supported by positive culture.
Genomic DNA extraction Genomic DNA was extracted from EDTA-anticoagulated peripheral blood using the DNA isolation kit. Briefly, 3 ml of blood was lysed in 9 ml of red blood cell lysis solution. Moreover, the suspended cells were added to 3 ml of cell lysis solution and pelleted. RNase and then protein precipitation solutions were added to the nuclear lysate. DNA in the supernatant was precipitated with isopropanol and washed with 70% ethanol.
Genomic DNA sequencing of FasL promoter The FasL promoter region was amplified using forward primer 5 0 -CTG AGG CAG GAG GAT GTC TCG-3 0 and reverse primer 5 0 -GAG GCT GAG GTG TCA AGG ACG-3 0 . The PCR amplification was conducted with 500 ng of DNA, 200 nM of each primer, 1.5 nM MgCl 2 , 200 mM dNTPs, and 1 U of Taq DNA polymerase in a 20 ml reaction volume. The temperature cycle was as follows: first 951C for 5 min, then 35 cycles of denaturation at 941C for 1 min, annealing at 561C for 1 min and extension at 721C for 1 min and 20 s, and finally an extension at 721C for 10 min. The PCR products were purified with a Gel extraction kit and directly sequenced using the BigDye terminator sequencing kit and an ABI 377 sequencer.
MALDI-TOF mass spectrometry high-throughput genotyping of FasL promoter polymorphisms After confirming the sequence, FasL promoter genotyping was performed using the MALDI-TOF mass spectrometer of the Genomic Medicine Research Core Laboratory. The FasL À844C/T polymorphism was amplified by 10 ng of genomic DNA in a 10-ml volume added to a 96-well PCR plate containing forward primer 5 0 -AGC CTG GGT GAC AGA GTG AG-3 0 and reverse primer 5 0 -CCT GCC GAT CAC CAT AAT TT-3 0 . Cycling conditions were 951C for 2 min, followed by 40 cycles of denaturation at 941C for 30 s, annealing at 581C for 30 s and extension at 721C. The cycle was completed with a final extension at 721C for 2 min. The 193-bp PCR products were automatically purified on the MALDI-TOF map I I/8 robotic platform using a BRUKER genopure ds magnetic bead DNA purification kit followed by extension reaction with an allelic extension primer 5 0 -CAA TGA AAA TGA AAA CAT TG-3 0 and dCTP, ddGTP, ddATP, and ddTTP termination mix. Cycling conditions were 941C for 2 min followed by 50 cycles of denaturation at 941C for 8 s, annealing at 521C for 8 s, and extension at 721C. The cycle was finished off with a final extension at 721C for 2 min. The allelespecific products were purified with the BRUKER genopure oligo magnetic bead DNA purification kit. The 3-hydroxypicolinic acid (3-HPA) matrix and analytes were automatically spotted on the 384-well Anchor Chip plate and analyzed via Autoflex mass spectrometry. The FasL À1094A/C polymorphism was amplified with forward primer 5 0 -GGA GGA TGT CTC GAA GCT A-3 0 and reverse primer 5 0 -CAG TGT GGT GCT ATC GTA GTT-3 0 . Primer extension of the 217-bp PCR products was performed using an allelic extension primer 5 0 -GAC AAG CCT GGG CAA CAT AG-3 0 and dATP, ddGTP, ddCTP, and ddTTP termination mix. Cycling conditions and purification procedures were the same as for À844C/T genotyping.
Statistical analysis
The frequency of genotypes and alleles of the two FasL promoter polymorphisms in patients and controls were compared using a w 2 test. Data were analyzed using the SPSS 10 statistics package for Windows. The distribution of variant genotypes was also compared between the lupus patients who were positive vs negative for various clinical manifestations and autoantibodies. A P-value p0.05 was considered significant.
